Wolverine Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-14,500
Closed -$344K 1766
2020
Q2
$344K Sell
14,500
-12,500
-46% -$276K ﹤0.01% 796
2020
Q1
$485K Buy
27,000
+13,700
+103% +$288K 0.01% 685
2019
Q4
$315K Buy
+13,300
New +$323K ﹤0.01% 890
2016
Q1
Sell
-70
Closed -$1K 1593
2015
Q4
$1K Hold
70
﹤0.01% 1640
2015
Q3
$1K Hold
70
﹤0.01% 1763
2015
Q2
$1K Hold
70
﹤0.01% 1813
2015
Q1
$1K Sell
70
-995
-93% -$9.4K ﹤0.01% 1767
2014
Q4
$19K Buy
1,065
+995
+1,421% +$8.36K ﹤0.01% 1637
2014
Q3
$5K Hold
70
﹤0.01% 2145
2014
Q2
$16K Sell
70
-450
-87% -$4.01K ﹤0.01% 1749
2014
Q1
$145K Buy
520
+330
+174% +$3.04K ﹤0.01% 990
2013
Q4
$38K Sell
190
-134
-41% -$937 ﹤0.01% 1863
2013
Q3
$13K Sell
324
-580
-64% -$3.9K ﹤0.01% 2181
2013
Q2
$43K Buy
+904
New +$5.32K ﹤0.01% 1754

Other funds holding SUPN

Wolverine Asset Management's SUPN Position: Q4 2019 in Review

Wolverine Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2019, closing a stake of 1,705 shares — an estimated $41.4K sold.

Wolverine Asset Management first reported a position in SUPN in Q2 2013 and held it in 13 quarters. The position peaked at $854K in Q2 2013. 235 funds tracked by Wall St. Rank hold SUPN as of Q4 2019.

  • Wolverine Asset Management reported no remaining Supernus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Wolverine Asset Management sold 1,705 Supernus Pharmaceuticals shares in Q4 2019, an estimated $41.4K.
  • Wolverine Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Wolverine Asset Management's Supernus Pharmaceuticals position peaked at $854K in Q2 2013.
  • 235 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2019.

Based on Wolverine Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.